Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially overexpressed relative to normal tissue in a variety of human adenocarcinomas, including endometrioid ...
MedPage Today on MSN7d
Mixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian CancerPromising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer – in one of the most ...
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...
In what marks a significant leap forward in precision oncology, the TROP2 (trophoblast cell surface antigen 2) antibody market is witnessing an accelerated growth in clinical trials and ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to regulatory approval in lung cancer, getting a green light in China for ...
*Because of the small number of events (deaths and progressions) in the G1 EEC category, the confidence interval was not reliable.
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback